ASX Release

Anatara Lifesciences receives $318,402 in R&D tax incentive for FY26

ADELAIDE, 15 September 2026: Anatara Lifesciences Ltd (ASX: ANR) ("Anatara" or "the Company") is pleased to report that the Company has received a refund of **$318,402** from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.

The refund received by Anatara will provide important funds for working capital and towards costs associated with its evaluation of additional opportunities and new strategic directions.

The Australian Government's R&D Tax Incentive supports companies undertaking eligible R&D activities by providing a tax offset for qualifying R&D expenditure.

This ASX announcement was approved by the Board of Anatara Lifesciences.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com